Suvratoxumab

Monoclonal antibody

none

IdentifiersCAS Number

1629620-18-3

ChemSpider

none

UNII

4L1997J4DF

KEGG

D11124

Chemical and physical dataFormulaC₆₅₅₆H₁₀₁₁₄N₁₇₃₀O₂₁₀₀S₄₄Molar mass148179.68 g·mol⁻¹

Suvratoxumab (INN;^[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.

This drug was developed by MedImmune^[2]

References

^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.

Monoclonal antibodies for infectious disease and toxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§